LAM 001

Drug Profile

LAM 001

Alternative Names: LAM-001

Latest Information Update: 18 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LAM Therapeutics
  • Class
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphangioleiomyomatosis

Most Recent Events

  • 18 Apr 2017 LAM Therapeutics completes a phase-I trial in Lymphangioleiomyomatosis in USA (LAM Therapeutics pipeline, April 2017)
  • 03 Feb 2016 Phase-I clinical trials in Lymphangioleiomyomatosis in USA (Inhalation) before February 2016
  • 31 Jan 2016 The US FDA approves IND application for LAM 001 in Lymphangioleiomyomatosis before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top